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ABSTRACTVaccines represent a useful contribution to the branch of biotechnology as they supply protection against various diseases. However, the major hurdleto oral immunization is the digestion of macromolecule antigenic protein within the stomach due to extremely acidic pH. To address this issue, scientistArntzen developed the theory of edible vaccines (EVs). EVs are developed using the genetic engineering technology in which the appropriate genes areintroduced into the plants using various methods. This genetically modified plant then produces the encoded protein which acts as a vaccine. Owingto its low cost, it will be affordable for developing countries like India. EVs are developed to treat various diseases such as malaria, measles, hepatitisB, stopping autoimmunity in type-1 diabetes, cholera, enterotoxigenic Escherichia coli (ETEC), HIV, and anthrax. This review comprises mechanism ofaction, methods of development, candidate plants, applications, and clinical trials of EVs.
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INTRODUCTION
VaccinesVaccines represent a useful contribution to the branch of biotechnologyas they supply protection against varied diseases. All organisms arevulnerable to one or more forms of infectious and noninfectious diseasesthroughout their life. To prevent these infection researchers discoveredplant-based vaccine which is an immune-biological substance, used forspecific protection against both infectious and noninfectious diseases.The process of distributing and administrating vaccines is referredto as vaccination and vaccination is a form of immunization [1-4].Typical vaccines consist of killed or live/attenuated disease-causingorganisms. Very few patients show a recurrence of the disease forwhich they have been vaccinated, thereby cutting down the cost ofexpensive treatment procedures [5]. Immunization is a two-century-old science of prophylaxis. Edward Jenner is regarded as the father ofimmunization as he was the first to study that inoculation of cowpoxvirus prevents small pox in human. After this discovery, the cowpoxvaccination came into clinical use worldwide in the 19th century. Thescience of immunization peaked to new heights in late 19th century toearly 20th century and during World War II [6-10].Administration of vaccines involves activation of the immune systemto prepare it for the event of an invasion from a particular pathogen forwhich the immune system has been primed. Vaccines are used for activeimmunization as a prophylactic measure against some infectious diseases.They provide partial or complete protection for months or years. Vaccinescan be given via various routes of administration, including oral, nasal,and parenteral routes such as intramuscular (IM), subcutaneous (SC), andintradermal (ID). It is well documented that the route of administration canimpact the type of immune response. The majority of commercial vaccinesare administered by IM or SC routes. The emergence of tissue culturetechniques revolutionized the immunization approaches. A number ofnew vaccines with different approaches - such as live/attenuated bacterialor viral vaccines, killed bacterial suspension, toxins produced by bacterialtoxoids, and rickettsial suspension - have been developed [10].
Difficulties in traditional vaccine systemsThe major limitations with conventional vaccines are their storage,transport under strictly controlled conditions (dependence on cold
chain system), and possibility of adverse reactions either due toreactions inherent to inoculation or because of faulty techniques.Criteria for standard oral vaccine system:i. Desired antigens should be present in adequate quantitiesii. Stability of expressed antigen at room temperature for a long timeiii. Protective immunity must be induced by the vaccineiv. Must withstand degradation by enzymes in the stomach [4,11,12].
The evolution of plant-derived vaccine technologySince the conventional vaccines have many limitations, this led to thesearch for new vaccines which are having flexibility in administration,storage, transportation and ultimately cost-effective. Hence, thereis a plenty of scope in developing plant-derived immunizing agent.Scientist’s counsel that plants and plant viruses are genetically builtto   provide vaccines   against   diseases.   Consequently,   some   studyshows plant-derived vaccines considerably increase availability ofvaccines in places wherever maintenance of cold conditions is tough.Developments in transgenic research have created the production oftransgenic plants expressing antigenic proteins which are induced byplant transgenic vectors. This will help to produce special vaccines withhigh anti-disease ability [13,14].During the last decade, different types of efficient plant-basedexpression systems have been studied, and more than 100 differenttypes of transgenic proteins including plant-derived vaccine antigenshave been successfully expressed in different types of plant tissues.Positive effects of edible vaccines (EVs) include the decrease inpotential hazards such as toxic compounds, responses to allergy, andrisk  of  attenuated  strains reverting to  pathogenic  strains.  The  EVshave several functions for either individual animals or humans byproviding long lasting immunity without risk of relapse reaction andfaulty techniques; there exists a lack of information regarding theirproduction and mechanism of action [15].
Concept of EVsThe concept of EVs was developed by Arntzen in the 1990s. The earliestdemonstration of an EV was the expression of a surface antigen fromthe bacteria Streptococcus mutans in tobacco. As this bacteria causes
Hirlekar and Bhairy
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 71-77dental caries, it had been suggested that the stimulation of a mucosalimmune response would stop the bacteria from colonizing the teethand therefore protect against tooth decay. Vaccine antigens can bedelivered orally by administration of transgenic edible parts whichare developed using the methods of molecular biology. The genesof interest can be introduced into plants where they are expressedin the plant tissues including the edible components. This processis known as “transformation” and the genetically modified plantsare referred as “transgenic plants.” These genes encode protectivevaccine antigens from viral, bacterial and parasitic pathogens thatcause disease in humans and animals. The vaccine can be deliveredby intake of the edible part of the genetically modified plant, or thehigh-yield production of refined protein for oral delivery EVs are likeunit preparations as they are built to contain antigens, however, bearno genes that might change whole pathogens to cause harmful effectsto humans (Fig. 1). Thus, they have no means of creating an infection,assuring its safety, particularly in immune-compromised patients.In comparison to traditional vaccines, EVs have a lot of compliance,especially in children, and due to oral administration, it eliminatesthe necessity of trained medical personnel. Their production is veryeconomical and can be easily scaled up. They are less expensive, heat-stable, do not require cold temperature maintenance, can be storednear the site of use. They do not require syringes and needles, exhibitgood genetic stability, can be grown regionally using standard methodsand do not require capital-intensive pharmaceutical manufacturingfacilities [16-20].
Properties of an ideal vaccinei. It should not be toxic or pathogenic, i.e., it should be safeii. It should have very low levels of side effects in normal individualsiii. It should not cause problems in individuals with impaired immunesystemiv. It should produce long-lasting humoral and cellular immunitiesv. The vaccination technique should be simplevi. The vaccine should be less expensivevii. Contamination of the environment should not happenviii. It should be effective and affordable [9,21,22].
Advantages and disadvantages of EVs
Advantagesi. They can be mass-produced. Hence, they are economicalii. They can be administered by eating the plant/part of the plant. Hence,the processing and purification steps can be eliminatediii. They can be stored at normal room temperature. Extensive coldstorage conditions are not requirediv. The process of transportation and distribution can be eliminated, ifthe local/native crop of a particular area is engineered to producethe vaccine
v. They trigger the body’s first line of defense (immunity at themucosal surfaces).
Disadvantagesi. Selection of plant with stable antigen production could be a difficulttask, time-consuming, and expensiveii. Lack of knowledge regarding plant biotechnology which leads tonegative public opinions, stringent laws, and debates regardingintellectual property discourage pharmaceutical businessinvestments in EVsiii. Possibility for hypersensitive reaction, development of oral toleranceto vaccines and also difficulty in the administration of the standarddose are additional limitations [23,24].
Mechanism of actionThe major drawback to oral vaccination is the digestion ofmacromolecule antigenic protein within the stomach due to extremelyacidic  pH. Edible  parts  of  plants  can  be fed  directly,  as  the  outerrobust wall of plant cells act to safeguard the antigens against attackby enzymes and secretions in the stomach by internal organs. Thisis described as bio-encapsulation. The plant cytomembrane breakswithin the intestine to release the antigens [25].The antigens are released taken up by M cells (specialized epithelialcells present in GIT with high capacity of transcytosis of a wide rangeof microbes and macromolecules) in the intestinal lining that overliePeyer’s patches (PPs). PPs (a group of lymphatic nodules also termedas aggregated lymphatic follicles) are an enriched source of secretoryimmunoglobulin (Ig) A which generate plasma cells and have apotential to populate mucosal tissue, and serve as mucosal immuneeffectors sites. The breakdown of EVs near PP causes antigenicstimulation of follicles and development of the germinal center. Theantigen penetrates through these follicles into the epithelium ofintestine, and these antigens accumulate within organized lymphoidtissues [26].The immune system composed of various constituents such as B-cell,T-cells, and macrophages is accumulated in lymphoid follicles. M-cellsexpressing class II Muco-histo-compatibility complex molecules andantigens transported across the mucous membrane by M-cells canactivate B-cells within these lymphoid follicles. The activated B-cellsleave the lymphoid follicles and migrate to diffuse mucosal-associatedlymphoid tissue to differentiate into plasma cells that secrete serumIgG, IgE, local IgA and generate memory cells, which would neutralizethe attack by the original infectious agent present in the body.Administration of EVs to mothers might be successful in immunizingthe fetus-in-utero by trans-placental transport of maternal antibodiesor the infant through breast milk [27-30].
Fig. 1: Concept/graphical abstract of edible vaccines
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METHODS FOR TRANSFORMATION OF DNA/GENE INTO PLANTSIt has been reported that the methods mentioned below are used fordevelopment of EVs. Fig. 2 depicts various methods for transformationof desired DNA/gene into plants.
Plasmid/vector carrier system: Agrobacterium tumifaciens
methodOne way of generating EVs depends on the microorganism species todeliver into plant cells the genetic blueprints for an infectious agent or
microorganism “antigens” proteins that elicit a targeted immunologicresponse within the recipient [13]. A. tumifaciens is present insoil which is employed to transfer a little phase of DNA into plantordination and this method is termed transformation. The whole plantis regenerated from an individual plant cell. It has been reported thatgenes which are expressed successfully in experimental model plants,when given orally to animals, generate serum antibodies. Vegetablepathogens, A. tumefaciens and Agrobacterium rhizogenes, havepotential to integrate their DNA (T-DNA) into the infected cell’s nucleargenome. The introduction of  exogenous genes into the adequately
Fig. 2: Schematic diagram showing various methods of production of plant based edible vaccines
Fig. 3: Schematic representation of plasmid/vector carrier system
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modified T-DNA of Agrobacterium cells and following infection of avegetable tissue led to the study of gene’s stable integration in theplant’s genome and production of a transgenic protein which acts asan EV (Fig. 3) [31-34].
Micro projectile bombardment (biolistics)/gene gun methodThe gene containing DNA-coated metal (e.g., gold and tungsten)particles are fired at the plant cells by means of the gene gun. Theseplant cells uptakes the DNA then permitted to grow in new plants andare cloned to supply a large amount of genetically similar crop. Thistechnique is more often suitable to deliver DNA into cells of the plantthat makes the transfer of genes independent of regeneration abilityof the species. However, the limitation is that the technique is noteconomical because of particle gun device [4,6,35].
Chimeric virus methodPlant viruses are genetically modified to carry the desired genes andused to infect their natural hosts such as the edible plants where thecloned  genes  are expressed to varying  degrees  in  different  edibleparts of the plant (Fig. 4). Certain viruses can be redesigned to expressfragments of antigenic proteins on their surfaces such as cowpea mosaicvirus, alfalfa mosaic virus, tobacco mosaic virus, cauliflower mosaicvirus (CaMV), potato virus, and tomato bushy stunt virus [4,36,37].
Electroporation methodThe introduction of DNA into cells is done by exposing the cells for a briefperiod to high voltage electrical pulse that is assumed to induce transientpores within the plasmalemma (a thin layer of tissue that covers surface).The cell wall acts an efficient barrier to DNA. Hence, it has to be weakenedby enzymatic treatment thus permit the entry of DNA into the cell [4,21].
CANDIDATES FOR EVsEdible parts of different species of plants plant, such as the grains orfruits, are utilized for the expression of the desired antigen of interest.Cereals like rice and maize, fruits like banana, leaves of many plants(tobacco, alfalfa, peanut leaves), tubers like potatoes, tomatoes, soybeanseeds, cowpea, pea, carrot, peanut, and lettuce have been extensivelyused for high levels of antigenic protein expression. The factors to beconsidered while selecting the vehicle for the vaccine: Plant should behardy, it should be palatable and well relished, it should be indigenous,easily available and transformation can be done easily [38-40].Several things have to be considered when selecting an expression host, likegene of interest to be expressed in leaves or in dry tissues like cereals basedon the final part to be used for the vaccination purpose. The advantagesof using grains as an expression host are many like it can store proteinsfor many years, is cost-effective, large volumes of desired products can beproduced in short span of time and can be easily harvested and processed.The generally used plant for expression of a protein is tobacco becauseof its transforming ability. The ultimate goal of using transgenic plants asproduction systems for animal and human vaccine antigens is to facilitateeasier delivery of immunizing antigen so that mass immunization can beachieved against infectious diseases [4,41-43].
BananaBananas are sterile so the genes do not pass from one banana toanother which is the main reason why bananas are a good choice foran EV. The tropical climate is suitable for growing bananas. Most third-world countries are found in this climate. It does not need cooking.Proteins are not destroyed even if cooked and it can be eaten as raw. It isinexpensive, can be grown widely in developing countries, grow quicklyand have the high vitamin A content which boosts immune response.Disadvantages are tree take 2-3 years to mature, transformed tree takeabout 12 months to bear fruits, spoils rapidly after ripening [44].
RiceAn EV using genetically altered rice is used in cholera treatment.Cholera vaccine exists   but   provides   short-lived   protection   andrequires refrigeration. It has been reported that a strain of rice canserve as a vaccine and last for more than a year and a half at normalroom temperature.  It  is  used  as  pediatric food  because  of  the  lowlevel of allergenic potential but grows slowly and requires specializedglasshouse condition [4].
MaizeMaize plants generate a protein that is used to develop the hepatitisB virus vaccine. It is cheaper and does not need to be refrigerated.A major disadvantage of this vaccine is to be cooked for use whichcauses degradation of proteins [14].
PotatoA potato based vaccine used to combat the Norwalk virus (stomachvirus), which is spread by contaminated water and food and causessevere abdominal pain and diarrhea. Potato has been also servedas  a vehicle for diabetes-related proteins, the vaccine against  astrain of Escherichia  coli, cholera vaccine.  A potato based vaccinehas advantages such as safely stimulating antibodies, affordable,and stored for a prolonged period without refrigeration. The majorlimitation is it needs cooking which can denature antigen and decreaseimmunogenicity [4,44].
TomatoIt has been reported that tomato can be served as a vector to developthe vaccines against anthrax, rabies and HIV/AIDS. It has merits suchas grows quickly, cultivated broadly, heat-stable, and high vitamin Acomposition may boost immune response. Antigen-containing powderscan be filled into capsules and with no requirement of special facilitiesfor storage and transportation. However, it has demerit as spoils easilyhence cannot be stored for over a long period [45].
TobaccoHuman papilloma viruses (HPV) are the causative agent for cervicalcancer and also involved in skin, head, and neck tumors. More than150 distinct classes of HPV are known. The most commonly foundHPVs in cervical carcinomas are HPV 16 and 18. Virus proteins E6and E7 are known as oncoproteins; these are the promising target forthe development of HPV-associate tumors. It has been reported that,when HPV16 E7 protein was introduced into the cytoplasm tobacco
Fig. 4: Schematic representation of chimeric virus method
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Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 71-77(Nicotiana benthamiana) plants, the E7 production level were of 15 µgof protein/g of fresh leaf) [46]. Tobacco plants are a good model forevaluating recombinant proteins and can be harvested a number oftimes in a year. However, due to the composition of a high level of toxicalkaloids, it causes more toxicity [47-49].
Miscellaneous candidatesSome other plants which can also be served for vaccine delivery arelettuce (fast-growing but, spoils readily), soybean (direct consumption,can be harvested a number of times in a year. but, spoils readily), andwheat (large number of seeds help in an increased harvest but needcooking) [47-49]. Table 1 enlists the various vaccines under clinicaldevelopment.
STABILITY AND PROCESSING OF PLANT-DERIVED VACCINESReliable strategies are required to quantify plant-derived antigens andfor their stability. Lee et al. reported that 50 fusion proteins containingthe Mannheimia haemolytica A1 leukotoxin were harvested using cloverplants as an expressing system and allowed to dry at temperatureambient humidity for 1 to 4 days. After 3 days, 20% of its initial freshweight of the clover tissue was retained but no significant degradationof the fusion protein was observed. Hence, the fusion protein did notrequire cold storage conditions for stability. When the clover-expressedfusion protein was injected into rabbits induced an immune responsethat recognized and neutralized the native antigen in modified neutralred cytotoxicity assays [33].Smith et al. performed a more comprehensive stability study. Thequantification of antigenically reactive Hbs Ags was found to bestrongly dependent on the ratio of detergent: Cell concentration.A 1-20% w/v sodium ascorbate concentration improved the measuredlevels of monoclonal-reactive antigen 4 to 12-fold. Antigen stabilitywas influenced by detergent in cell lysates stored at 48°C. Underoptimum conditions, stability was maintained for at least 1 month;proteolytic degradation was observed when stored with excessdetergent concentration. Proteolysis was counteracted by the additionof skimmed milk or its protein component; this stabilizes the antigenfor up to 2 months [52].Castanon et al. investigated the minimal processing of a potato-derivedrabbit hemorrhagic disease virus (RHDV) vaccine consisting of theVP60 gene. Harvested potatoes were peeled, cut into pieces, lyophilized,powdered, stored and used in trials within 3 months of collection. Rabbitswere primed SC and boosted IM with extracts made from the potatopowder. The rabbits immunized with the transgenic potato inducedspecific antibody responses and were protected against RHDV [53,54].
REGULATORY ASPECTS/ISSUESIt has to be set whether or not EVs would be regulated underneath food,medicine or agricultural product. Further, it is undecided that licensing
shall be needed for the antigenic protein or genetically built fruit ortransgenic seeds. The transgenic plants need greenhouse segregationand separate bodies that make sure that such plants are not rereleasingthe antigenic proteins in the environment by any means. Transgenesmay spread by sucking insects, pollen and transfer to soil microbesduring plant wounding or breakdown of roots and may pollute surfaceand ground water. Ethical considerations usually restrict clinical trialsfrom directly assessing protection in humans [26].
APPLICATIONS OF EVs
MalariaSeveral strategies have been tested to combat malaria and innumerableattempts have been made to launch a malaria vaccine [55]. Threeantigens are under investigation for the development of EVs, merozoitesurface  protein  (MSP)  4  and  MSP  5  from Plasmodium  falciparum,and MSP4/5 from Plasmodium yoelii. Wang et al. have reported thatoral administration of recombinant MSP 4, MSP 4/5 and MSP1, co-administered with cholera toxin B (CTB) as a mucosal adjuvant to amice, induced antibody responses effective against the blood-stageparasite. It has been suggested that antigen expression level in plantsis low, this requires the administration of a large quantity of plantmaterial to achieve the desired immunity. Moreover, due to the highdegree of antigen anticipated to be necessary, it is likely that strongadjuvant will also be required [6,56,57].
MeaslesThe vaccine currently in use produces 95% seroconversion (It is theperiod of time during which a specific antibody develops and becomesdetectable in blood) in individuals who are over the age of 18 months atthe time of vaccination. Measles live-attenuated vaccine does not induceoral immunization effect and destroyed by heat. Hence, refrigeration isthe prerequisite for its storage. Maternal antibodies also reduce theimmunization response of vaccine. Measles virus hemagglutinin (MV-H)from edmonston strain antigen was selected for the development of anEV, which can be transformed into tobacco plant by plasmid/vector. Itwas also reported that mice fed with tobacco expressing MV-H couldattain antibody titers 5 times the level considered protective for humansand they also demonstrated secretory IgA in their feces [19,58-60].Oral administration of MV-H encapsulated transgenic plant extractinduced serum antibodies, which neutralized the wild-type MV andretained  its  immunogenicity. Results  indicated  that  IgA  antibodieswere found in the fecal samples of animals immunized orally with plantderived MV-H. It has also been studied that transgenic carrot plantcould be used to deliver viral antigens for the development of measlesvaccine [6].
Hepatitis BIt was reported that the ingestion of single potato was able to providethe amount of HBs Ag needed for one dose. Levels of specific antibodies
Table 1: Plant-origin pharmaceutical proteins developed clinically with designated medical applications [50,51]
Product Plant host Indication Route of Product
administration stage
developmentVaccine containing E. coli heat labile toxin Potato, maize Diarrhea Oral Phase 1Norwalk virus vaccine Potato, tobacco, tomato Sickness and diarrhea Oral Phase 1Hepatitis B surface antigens (HBsAg) IgG Potato, banana, tobacco, Hepatitis B Oral Phase 1(hepatitis B virus) cherry, tomato, lettuceRabies virus glycoprotien/nucleoprtien antibodies Spinach, tobacco Rabies Oral Phase 1Single chain viable region vaccine Tobacco Non-hodgkins lymphoma Oral Phase-1 trialsAvicidin Maize Colorectal cancer Oral Withdrawnfrom Phase-IItrialsGastric lipase Maize Cystic fibrosis, pancreatitis Oral Phase-IILactoferrin Maize Gastrointestinal infections Oral Phase-IIHuman intrinsic factor Arabidopsis Vitamin B12 deficiency Oral Phase-II
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Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 71-77significantly exceeded the protective level of 10 mIU/mL in humans.When cloned into CaMv, plasmid HBsAg subtype ayw showed higherexpression in roots as compared to leaf tissue of the geneticallymodified potato. Tomatoes expressing HBsAg are being grown inguarded greenhouses. It was demonstrated that 30 tomato plants wereable to provide enough antigens for 4,000 vaccine doses [61,62].
Stopping autoimmunityIngesting autoantigens (proteins derived from uninfected tissue in atreated individual), or “self-antigens,” might suppress autoimmunity intype I diabetes. Type I diabetes progresses silently for a time. Eventually,though, the loss of beta cells causes a drastic shortage of insulin, whichresults in high blood sugar levels. Insulin injections can be used tocontrol diabetes, but they are by no means a cure. It has been reportedthat the plant-based diabetes vaccines such as potatoes containinginsulin or glutamic acid decarboxylase linked to the innocuous B subunitof the Vibrio cholera toxin (to enhance uptake of the antigens by M cells)when administered to a diabetic mouse helped to suppress the immuneattack and to prevent or delay the onset of high blood sugar [30,63].
CholeraGenetically modified potatoes expressing CTB were found to produceboth serum and secretory antibodies when fed to mice. Since peopleeat only cooked potatoes, the effect of boiling on the properties of CTBexpressed in transgenic potatoes was examined. It was evidenced that,over half of the vaccine protein survived in its biologically active formeven after boiling for five minutes and this proves that cooking does notalways inactivate EVs [64-66].
Enterotoxicogenic E. coli (ETEC)It has been reported that when 11 volunteers were fed raw geneticallymodified potatoes containing heat-labile enterotoxin B, 10 (91%)of these volunteers generated neutralizing antibodies and 6 (55%)generated a mucosal response against ETEC [67].
Norwalk virusNineteen (95%) out of 20 people when administered transgenic potatoexpressing Norwalk virus antigen developed seroconversion. Geneticallyengineered bananas and powdered tomatoes expressing Norwalk virusare under development phase to combat Norwalk virus [67].
HIVGenetically modified tomatoes were developed by injecting two HIVprotein genes along with promoters such as CaMV with a needle andthe expressed protein was demonstrable by polymerase chain reactionin different parts of the plant, including the ripe fruit, as well as inthe second- generation plant. Recently, spinach has been successfullyinoculated for Tat protein expression cloned into TMV. Each gram of leaftissue of spinach was able to contain up to 300-500 mg of Tat antigen.Higher antibody titers were observed than the controls when micewere fed with this spinach [68,69].
AnthraxTobacco   leaves   bombarded   with   pag   gene   (anthrax   protectiveantigen [PA]) using a gene gun could express a protein structurallyidentical to the major protein present in existing vaccine. Billions ofunits of anthrax antigen could be produced. This vaccine was lackingedema factor  and  lethal factor which  are responsible for  potentialtoxic side effects. The same anthrax antigen is now being put in tomatoplants. It was also suggested that transgenic spinach might be a safervaccine upon inoculating it with TMV-expressing PA [70].
FUTURE DIRECTIONSThe future of EVs depends on following factors:• Socio-cultural acceptability of genetically changed plants,• Stability of genetically modified varieties and• Proper segregation of transgenic plants, prevention of environmentcontamination and prevention of potent side effects of transgenesas allergens.
EVs can be safe and effective modes of immunization and are betteras compared to the traditional vaccines when mass production,distribution, and delivery are concerned. Therefore, there is a need forthe development of a cost-effective, efficient and safe delivery.
CONCLUSIONEVs are the milestone in the branch of biotechnology for developinginexpensive vaccines that are particularly useful in immunizing peoplein  developing  countries, where  high  cost,  transportation  and  theneed for cold storage conditions, are hampering effective vaccinationprograms. Edible plant-based vaccine may lead to a future of safer andmore effective immunization. The expectation is that EVs may be fullygrown in many of the developing countries where they would actuallybe used.
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